BioCryst Pharmaceuticals, Inc. (BCRX)
8.17
+0.05
(+0.62%)
USD |
NASDAQ |
Oct 02, 16:00
8.15
-0.02
(-0.24%)
After-Hours: 20:00
BioCryst Pharmaceuticals Max Drawdown (5Y) : 79.10% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 79.10% |
| August 31, 2026 | 79.10% |
| July 31, 2026 | 79.10% |
| June 30, 2026 | 79.10% |
| May 31, 2026 | 79.10% |
| April 30, 2026 | 79.10% |
| March 31, 2026 | 79.10% |
| February 28, 2026 | 79.10% |
| January 31, 2026 | 79.10% |
| December 31, 2025 | 79.10% |
| November 30, 2025 | 79.10% |
| October 31, 2025 | 79.10% |
| September 30, 2025 | 79.10% |
| August 31, 2025 | 79.10% |
| July 31, 2025 | 79.10% |
| June 30, 2025 | 79.10% |
| May 31, 2025 | 79.10% |
| April 30, 2025 | 79.10% |
| March 31, 2025 | 88.16% |
| February 28, 2025 | 90.24% |
| January 31, 2025 | 90.24% |
| December 31, 2024 | 90.24% |
| November 30, 2024 | 90.24% |
| October 31, 2024 | 90.33% |
| September 30, 2024 | 90.33% |
| Date | Value |
|---|---|
| August 31, 2024 | 90.33% |
| July 31, 2024 | 90.33% |
| June 30, 2024 | 90.33% |
| May 31, 2024 | 90.33% |
| April 30, 2024 | 90.33% |
| March 31, 2024 | 90.33% |
| February 29, 2024 | 90.33% |
| January 31, 2024 | 90.33% |
| December 31, 2023 | 90.33% |
| November 30, 2023 | 90.33% |
| October 31, 2023 | 90.33% |
| September 30, 2023 | 90.33% |
| August 31, 2023 | 90.33% |
| July 31, 2023 | 90.33% |
| June 30, 2023 | 90.33% |
| May 31, 2023 | 90.33% |
| April 30, 2023 | 90.33% |
| March 31, 2023 | 90.33% |
| February 28, 2023 | 90.33% |
| January 31, 2023 | 90.33% |
| December 31, 2022 | 90.33% |
| November 30, 2022 | 90.33% |
| October 31, 2022 | 90.33% |
| September 30, 2022 | 90.33% |
| August 31, 2022 | 90.33% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Amgen, Inc. | 24.86% |
| Halozyme Therapeutics, Inc. | 49.06% |
| Neurocrine Biosciences, Inc. | 46.39% |
| Vertex Pharmaceuticals, Inc. | 41.60% |
| Agenus, Inc. | 98.84% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -19.65 |
| Beta (5Y) | 0.5526 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 52.41% |
| Historical Sharpe Ratio (5Y) | -0.2694 |
| Historical Sortino (5Y) | -0.5282 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 18.70% |